University of Arizona

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Arizona sits in the top decile of US sponsors by registered trial count (#101 of 15,742 sponsors by registered trial count).

349 total trials 56 currently recruiting 213 completed early-phase tilt top decile by trial count

University of Arizona: 349 sponsored US clinical trials, 56 recruiting.

University of Arizona sponsors 349 registered US clinical trials on ClinicalTrials.gov, 56 of them currently recruiting, and 213 completed. 21 of these trials are in Phase 3-4 (later-stage) and 100 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 6 trials.

Top-decile sponsor footprint

University of Arizona ranks in the top decile of sponsors by registered trial count (#101 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

213 of 260 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

349 total, page 7 of 7

COMPLETED NA

Influenza Vaccination in the Emergency Department

NCT00822627

COMPLETED

Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis

NCT00796809

COMPLETED NA

The Vegetable Dose Response Study: Effects of Consumption on Inflammation and Oxidative Stress

NCT01454674

COMPLETED Phase 1

Human Breast Tissue Bioavailability of Topically Applied Limonene

NCT01459172

COMPLETED Phase 4

Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome

NCT00822679

COMPLETED Phase 1

Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer

NCT00702299

TERMINATED Phase 1

Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment

NCT00614666

COMPLETED Phase 2

Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer

NCT00693719

COMPLETED Phase 1

Topical Myristyl Nicotinate Cream on the Skin of Healthy Volunteers

NCT00619060

COMPLETED Phase 1

Personalized Exercise for Adolescents With Diabetes

NCT00686283

COMPLETED NA

Jump-In: Building Better Bones

NCT00729378

COMPLETED Phase 4

Duloxetine for Perimenopausal Depression

NCT00517985

COMPLETED

Diagnosis of Exercise-induced Bronchospasm (EIB) and Asthma in National Collegiate Athletic Association (NCAA) Division I Athletes

NCT00752167

COMPLETED Phase 2

Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin

NCT00601640

COMPLETED Phase 1

Telephone Counseling: Men With Prostate Cancer & Partners

NCT00822510

COMPLETED

Identifying Inflammatory Biomarkers of Chronic Obstructive Pulmonary Disease

NCT00394940

COMPLETED Phase 4

A Pilot Study of Effect of Dexmedetomidine on Sleep and Inflammation in Critically Ill Patients

NCT00405847

COMPLETED Phase 2

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL

NCT00732498

TERMINATED Phase 2

Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

NCT00698685

COMPLETED NA

CHOICES: Family Physicians Treat Overweight Children

NCT01674920

COMPLETED Phase 1

Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors

NCT01172028

COMPLETED

Studying Tumor Tissue Samples From Patients With Soft Tissue Sarcoma

NCT00900341

COMPLETED Phase 2

Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer

NCT00130520

COMPLETED Phase 4

Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)

NCT00251732

TERMINATED Phase 3

Selenium for Prevention of Adenomatous Colorectal Polyps

NCT00078897

COMPLETED Phase 2

Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer

NCT00699907

COMPLETED Phase 2

Acupuncture as Complementary Therapy for Cerebral Palsy

NCT00221247

COMPLETED Phase 1

Green Tea Extract (Polyphenon E) in Preventing Cancer in Healthy Participants

NCT00091325

COMPLETED NA

Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries

NCT00098800

COMPLETED

Immune Response in Peripheral Blood of Patients With Colon Cancer

NCT00900432

COMPLETED Phase 2

Use of Omega-3 Fatty Acids for Perinatal Depression

NCT00402389

COMPLETED Phase 2

Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses

NCT00608634

COMPLETED Phase 4

Atomoxetine Pilot Study in Preschool Children With ADHD

NCT00517647

COMPLETED NA

The Effects of a 16-Week Individualized, Intensive Strength Training Program in Patients With Rheumatoid Arthritis

NCT00327275

COMPLETED NA

Moderate Physical Activity in Helping Patients Recover Physically and Emotionally From Stage II Or Stage III Colorectal Cancer

NCT00373022

COMPLETED NA

Community-Based Programs for Improving Physical Function in People With Early Knee Osteoarthritis

NCT00586300

COMPLETED

Neurological Effects of Chemotherapy and Radiation Therapy in Patients With Colon Cancer

NCT00410618

COMPLETED Phase 2

Selenium in Treating Patients With Prostate Cancer

NCT00752739

COMPLETED

Multidisciplinary Study of Right Ventricular Dysplasia

NCT00024505

COMPLETED

Studying Blood Samples in Women With Breast Cancer or a History of Breast Cancer

NCT00898703

COMPLETED Phase 2

Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis

NCT00021294

COMPLETED Phase 1

Family Consultation for Health-Compromised Smokers

NCT00400751

COMPLETED NA

Echinacea Purpurea and Osteopathy in Children With Recurrent Otitis Media

NCT00689468

COMPLETED Phase 1

Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome

NCT00003415

COMPLETED Phase 2

Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer

NCT00003307

COMPLETED Phase 1

Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer

NCT00003082

COMPLETED Phase 2

High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer

NCT00003068

COMPLETED Phase 2

Bone Estrogen Strength Training

NCT00000399

COMPLETED Phase 3

Bupropion Treatment for Youth Smoking Cessation

NCT00344695

← Previous Page 7 of 7

Phase Distribution

PhaseTrial count
Phase 1 43
Phase 2 57
Phase 3 8
Phase 4 13

What is open in the University of Arizona pipeline

56 recruiting of 349 indexed (16% open); 213 completed (61%).

Phase mix: 21 late (III/IV) vs 100 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (6 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Arizona: open-pipeline peers nationwide

Peers matched on 349 registered trials and 16% open enrollment, not the therapeutic-area sidebar.

University of Arizona sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20%25% Total trials Recruiting share University of ArizonaMontefiore Medical CenterNational Institute of Mental Health (NIMH)Children's Oncology GroupOhio State University Comprehensive Cancer CenterECOG-ACRIN Cancer Research GroupGeorge Mason UniversityUniversity of California, San FranciscoNational Human Genome Research Institute (NHGRI)
University of Arizona sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Arizona sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 349 trials (± recruiting share)

Sponsors near 16% open enrollment (± trial volume)

What to do with this University of Arizona page

349 registered trials is a research-attention snapshot, not an endorsement of University of Arizona or any single study.

  • 56 of University of Arizona's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition University of Arizona studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Arizona pipeline card: 349 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.